BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38243318)

  • 1. The genomic alterations in glioblastoma influence the levels of CSF metabolites.
    Wang DH; Fujita Y; Dono A; Rodriguez Armendariz AG; Shah M; Putluri N; Pichardo-Rojas PS; Patel CB; Zhu JJ; Huse JT; Parker Kerrigan BC; Lang FF; Esquenazi Y; Ballester LY
    Acta Neuropathol Commun; 2024 Jan; 12(1):13. PubMed ID: 38243318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors.
    Ballester LY; Lu G; Zorofchian S; Vantaku V; Putluri V; Yan Y; Arevalo O; Zhu P; Riascos RF; Sreekumar A; Esquenazi Y; Putluri N; Zhu JJ
    Acta Neuropathol Commun; 2018 Aug; 6(1):85. PubMed ID: 30170631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
    Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
    Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.
    Nakamizo S; Sasayama T; Shinohara M; Irino Y; Nishiumi S; Nishihara M; Tanaka H; Tanaka K; Mizukawa K; Itoh T; Taniguchi M; Hosoda K; Yoshida M; Kohmura E
    J Neurooncol; 2013 May; 113(1):65-74. PubMed ID: 23456655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations.
    Liu HQ; Li WX; An YW; Wu T; Jiang GY; Dong Y; Chen WX; Wang JC; Wang C; Song S
    Int J Immunopathol Pharmacol; 2022; 36():3946320221139262. PubMed ID: 36377597
    [No Abstract]   [Full Text] [Related]  

  • 12. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1
    Kondo N; Barth RF; Miyatake SI; Kawabata S; Suzuki M; Ono K; Lehman NL
    J Neurooncol; 2017 May; 133(1):107-118. PubMed ID: 28534152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
    Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
    Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging.
    Kampa JM; Kellner U; Marsching C; Ramallo Guevara C; Knappe UJ; Sahin M; Giampà M; Niehaus K; Bednarz H
    Neuropathology; 2020 Dec; 40(6):546-558. PubMed ID: 32662157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.
    Tuna G; Dal-Bekar NE; Akay A; Rükşen M; İşlekel S; İşlekel GH
    J Neuropathol Exp Neurol; 2022 Jun; 81(7):502-510. PubMed ID: 35582888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
    Lai A; Kharbanda S; Pope WB; Tran A; Solis OE; Peale F; Forrest WF; Pujara K; Carrillo JA; Pandita A; Ellingson BM; Bowers CW; Soriano RH; Schmidt NO; Mohan S; Yong WH; Seshagiri S; Modrusan Z; Jiang Z; Aldape KD; Mischel PS; Liau LM; Escovedo CJ; Chen W; Nghiemphu PL; James CD; Prados MD; Westphal M; Lamszus K; Cloughesy T; Phillips HS
    J Clin Oncol; 2011 Dec; 29(34):4482-90. PubMed ID: 22025148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients.
    Ferrer VP
    Cancer Genet; 2023 Jan; 270-271():22-30. PubMed ID: 36436416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.